Key Insights

Highlights

Success Rate

94% trial completion (above average)

Published Results

14 trials with published results (23%)

Research Maturity

51 completed trials (82% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

4.8%

3 terminated out of 62 trials

Success Rate

94.4%

+7.9% vs benchmark

Late-Stage Pipeline

26%

16 trials in Phase 3/4

Results Transparency

27%

14 of 51 completed with results

Key Signals

14 with results94% success

Data Visualizations

Phase Distribution

46Total
Not Applicable (13)
Early P 1 (1)
P 1 (12)
P 2 (4)
P 3 (6)
P 4 (10)

Trial Status

Completed51
Unknown5
Terminated3
Recruiting2
Withdrawn1

Trial Success Rate

94.4%

Benchmark: 86.5%

Based on 51 completed trials

Clinical Trials (62)

Showing 20 of 20 trials
NCT06709521Phase 4RecruitingPrimary

Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI)

NCT07285785Phase 4Recruiting

Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea

NCT02598141Not ApplicableCompletedPrimary

Grinding Versus Standard Methods for the Treatment of Per-operative Bacteriological Samples Associated With Osteo-articular Sepsis

NCT07122596Phase 4Completed

EFFICACY OF PROLONGED INFUSION MEROPENEM IN CRITICALLY ILL PAEDIATRIC INTENSIVE CARE PATIENTS

NCT05590728Phase 1CompletedPrimary

Safety of Intravenous Apramycin in Adults

NCT05645757Phase 1CompletedPrimary

Safety Study of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777)

NCT03910673Phase 1CompletedPrimary

Intravenous Fosfomycin Pharmacokinetics Study

NCT04479657Early Phase 1Unknown

Qingfei Granule for the Treatment of the Pediatric Acute Upper Respiratory Tract Infection With Bacterial Infection

NCT03978091Phase 1CompletedPrimary

A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam

NCT02436876Phase 2CompletedPrimary

Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites

NCT01250574CompletedPrimary

Neutrophil CD64 and Procalcitonin as Novel Biomarkers for Postoperative Infections

NCT01817075Phase 3CompletedPrimary

Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant

NCT01371656Phase 3Completed

Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation

NCT03369951Phase 4CompletedPrimary

Minocycline Pharmacokinetics (ACUMIN)

NCT04550767CompletedPrimary

: Bacterial Infections in Injecting Drug Users

NCT01892358Not ApplicableCompletedPrimary

Preventing Bacterial and Viral Infections Among Injection Drug Users

NCT02533609Unknown

Elimination of Antibiotics During Citrate-anticoagulated Continuous-veno-venous-haemodialysis

NCT02294175Not ApplicableCompleted

Larval Debridement Therapy Versus Sharp Debridement to Remove Biofilm

NCT01271998Phase 1CompletedPrimary

Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg

NCT02794831CompletedPrimary

Exposure to NSAIDs (Non Steroidal Anti-Inflammatory Drugs) and Severity of Community-acquired Bacterial Infections

Scroll to load more

Research Network

Activity Timeline